Bayer on Tuesday said it has applied to the European Medicines Agency (EMA) for marketing authorisation for its menopause symptom relief drug elinzanetant. A third late-stage study has shown that taking the pills daily alleviates hot flashes, providing supporting data on efficacy and long-term safety.